Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report

A patient with Prader-Willi syndrome (PWS), extreme obesity and hyperglycemia had her body weight increased considerably for 6 months, even with exercise and diet programs. Treatment with metformin and empagliflozin (12.5 mg/day) induced a weight loss of 14 kg (−10.3%) for 6 months and the reduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Farinha, Juliano Boufleur, Weinert, Letícia Schwerz, Costa, Lidiane Pozza, Costa, Marcelo Zanusso, de Peres, Patrícia Peres, Lorea, Cláudia Fernandes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer India 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042659/
https://www.ncbi.nlm.nih.gov/pubmed/35495777
http://dx.doi.org/10.1007/s13410-022-01076-1
_version_ 1784694708020183040
author Farinha, Juliano Boufleur
Weinert, Letícia Schwerz
Costa, Lidiane Pozza
Costa, Marcelo Zanusso
de Peres, Patrícia Peres
Lorea, Cláudia Fernandes
author_facet Farinha, Juliano Boufleur
Weinert, Letícia Schwerz
Costa, Lidiane Pozza
Costa, Marcelo Zanusso
de Peres, Patrícia Peres
Lorea, Cláudia Fernandes
author_sort Farinha, Juliano Boufleur
collection PubMed
description A patient with Prader-Willi syndrome (PWS), extreme obesity and hyperglycemia had her body weight increased considerably for 6 months, even with exercise and diet programs. Treatment with metformin and empagliflozin (12.5 mg/day) induced a weight loss of 14 kg (−10.3%) for 6 months and the reduction of glycated hemoglobin A(1c).
format Online
Article
Text
id pubmed-9042659
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer India
record_format MEDLINE/PubMed
spelling pubmed-90426592022-04-27 Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report Farinha, Juliano Boufleur Weinert, Letícia Schwerz Costa, Lidiane Pozza Costa, Marcelo Zanusso de Peres, Patrícia Peres Lorea, Cláudia Fernandes Int J Diabetes Dev Ctries Case Report A patient with Prader-Willi syndrome (PWS), extreme obesity and hyperglycemia had her body weight increased considerably for 6 months, even with exercise and diet programs. Treatment with metformin and empagliflozin (12.5 mg/day) induced a weight loss of 14 kg (−10.3%) for 6 months and the reduction of glycated hemoglobin A(1c). Springer India 2022-04-27 2022-10 /pmc/articles/PMC9042659/ /pubmed/35495777 http://dx.doi.org/10.1007/s13410-022-01076-1 Text en © The Author(s), under exclusive licence to Research Society for Study of Diabetes in India 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Case Report
Farinha, Juliano Boufleur
Weinert, Letícia Schwerz
Costa, Lidiane Pozza
Costa, Marcelo Zanusso
de Peres, Patrícia Peres
Lorea, Cláudia Fernandes
Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report
title Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report
title_full Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report
title_fullStr Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report
title_full_unstemmed Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report
title_short Efficacy of empagliflozin for weight and glycemic control of a patient with Prader-Willi syndrome, systemic lymphedema and extreme obesity: a case report
title_sort efficacy of empagliflozin for weight and glycemic control of a patient with prader-willi syndrome, systemic lymphedema and extreme obesity: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042659/
https://www.ncbi.nlm.nih.gov/pubmed/35495777
http://dx.doi.org/10.1007/s13410-022-01076-1
work_keys_str_mv AT farinhajulianoboufleur efficacyofempagliflozinforweightandglycemiccontrolofapatientwithpraderwillisyndromesystemiclymphedemaandextremeobesityacasereport
AT weinertleticiaschwerz efficacyofempagliflozinforweightandglycemiccontrolofapatientwithpraderwillisyndromesystemiclymphedemaandextremeobesityacasereport
AT costalidianepozza efficacyofempagliflozinforweightandglycemiccontrolofapatientwithpraderwillisyndromesystemiclymphedemaandextremeobesityacasereport
AT costamarcelozanusso efficacyofempagliflozinforweightandglycemiccontrolofapatientwithpraderwillisyndromesystemiclymphedemaandextremeobesityacasereport
AT deperespatriciaperes efficacyofempagliflozinforweightandglycemiccontrolofapatientwithpraderwillisyndromesystemiclymphedemaandextremeobesityacasereport
AT loreaclaudiafernandes efficacyofempagliflozinforweightandglycemiccontrolofapatientwithpraderwillisyndromesystemiclymphedemaandextremeobesityacasereport

Ejemplares similares